Biogen Inc. has announced that it will present new findings at the upcoming 2025 Alzheimer's Association International Conference in Toronto, Canada, from July 27-31. The presentations will include 48-month results from the Clarity AD open-label extension study on LEQEMBI® (lecanemab), offering insights into real-world treatment and a subcutaneous formulation for maintenance dosing. Additionally, Biogen will present baseline characteristics from CELIA, a Phase 2 trial evaluating BIIB080, an investigational antisense oligonucleotide therapy targeting tau. These findings aim to advance the understanding and treatment of Alzheimer's disease. The results are set to be presented during the conference.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。